BDTX BLACK DIAMOND THERAPEUTICS INC Product Launches 8-K Filing 2023 - Clinical Data Announcement Black Diamond Therapeutics announced initial clinical data from the Phase 1 study of BDTX-1535, showing anti-tumor activity in non-small cell lung cancer patients with EGFR mutations.Get access to all SEC 8-K filings of the BLACK DIAMOND THERAPEUTICS INC